1. Influence of immunogenicity on the long-term efficacy of infliximab in Chron’s disease;Baert;N. Engl. J. Med.,2003
2. Removal of therapeutic anti-lymphocyte antibodies from human sera prior to anti-human leukocyte antibody testing;Bearden;J. Immunol. Methods,2005
3. Predictive power of preclinical studies in animals for the immunogenicity of recombinant therapeutic proteins in humans;Bugelski;Curr. Opin. Mol. Ther.,2004
4. Monoclonal antibodies, immunogenicity, and associated infusion reactions;Cheifetz;Mt. Sinai. J. Med.,2005
5. European Medicines Agency (EMEA), Committee for Medicinal Products for Human Use (CHMP). Guideline on immunogenicity assessment of biotechnology-derived therapeutic proteins. EMEA/CHMP/BMWP/14327/2006. .